Anthony Marucci, Celldex CEO

Celldex flesh­es out case for Xo­lair chal­lenger in chron­ic hives

Celldex Ther­a­peu­tics is de­tail­ing more da­ta from a Phase I tri­al, close to eight months af­ter shar­ing ini­tial re­spons­es from an in­ter­im analy­sis.

The New …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.